Riess H - Search Results

1

Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.

Riess H, Ay C, Bauersachs R, Becattini C, Beyer-Westendorf J, Cajfinger F, Chau I, Cohen AT, Khorana AA, Maraveyas A, Renni M, Young AM. Riess H, et al. Oncologist. 2018 Jul;23(7):822-839. doi: 10.1634/theoncologist.2017-0473. Epub 2018 Apr 12. Oncologist. 2018. PMID: 29650686 Free PMC article. Review.

2

Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions.

Riess H, Prandoni P, Harder S, Kreher S, Bauersachs R. Riess H, et al. Crit Rev Oncol Hematol. 2018 Dec;132:169-179. doi: 10.1016/j.critrevonc.2018.09.015. Epub 2018 Sep 29. Crit Rev Oncol Hematol. 2018. PMID: 30447923 Review.

3

Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management.

Riess H, Verhamme P, Weitz JI, Young A, Bauersachs R, Beyer-Westendorf J, Crowther M, Maraveyas A. Riess H, et al. Crit Rev Oncol Hematol. 2021 Jan;157:103125. doi: 10.1016/j.critrevonc.2020.103125. Epub 2020 Oct 20. Crit Rev Oncol Hematol. 2021. PMID: 33254037 Review.

4

Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism.

Beyer-Westendorf J, Klamroth R, Kreher S, Langer F, Matzdorff A, Riess H. Beyer-Westendorf J, et al. Among authors: riess h. Dtsch Arztebl Int. 2019 Jan 18;116(3):31-38. doi: 10.3238/arztebl.2019.0031. Dtsch Arztebl Int. 2019. PMID: 30832760 Free PMC article.

5

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Khorana AA, et al. Among authors: riess h. N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. N Engl J Med. 2019. PMID: 30786186 Clinical Trial.

6

Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.

Vadhan-Raj S, McNamara MG, Venerito M, Riess H, O'Reilly EM, Overman MJ, Zhou X, Vijapurkar U, Kaul S, Wildgoose P, Khorana AA. Vadhan-Raj S, et al. Among authors: riess h. Cancer Med. 2020 Sep;9(17):6196-6204. doi: 10.1002/cam4.3269. Epub 2020 Jul 14. Cancer Med. 2020. PMID: 32663379 Free PMC article. Clinical Trial.

7

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.

Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. Farge D, et al. Lancet Oncol. 2022 Jul;23(7):e334-e347. doi: 10.1016/S1470-2045(22)00160-7. Lancet Oncol. 2022. PMID: 35772465 Free PMC article. Review.

8

The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis.

van Es N, Ventresca M, Di Nisio M, Zhou Q, Noble S, Crowther M, Briel M, Garcia D, Lyman GH, Macbeth F, Griffiths G, Iorio A, Mbuagbaw L, Neumann I, Brozek J, Guyatt G, Streiff MB, Baldeh T, Florez ID, Gurunlu Alma O, Agnelli G, Ageno W, Marcucci M, Bozas G, Zulian G, Maraveyas A, Lebeau B, Lecumberri R, Sideras K, Loprinzi C, McBane R, Pelzer U, Riess H, Solh Z, Perry J, Kahale LA, Bossuyt PM, Klerk C, Büller HR, Akl EA, Schünemann HJ; IPDMA Heparin Use in Cancer Patients Research Group. van Es N, et al. Among authors: riess h. J Thromb Haemost. 2020 Aug;18(8):1940-1951. doi: 10.1111/jth.14824. Epub 2020 Jul 8. J Thromb Haemost. 2020. PMID: 32336010 Free article.

9

Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial.

Khorana AA, McNamara MG, Kakkar AK, Streiff MB, Riess H, Vijapurkar U, Kaul S, Wildgoose P, Soff GA; CASSINI Investigators. Khorana AA, et al. Among authors: riess h. TH Open. 2020 May 23;4(2):e107-e112. doi: 10.1055/s-0040-1712143. eCollection 2020 Apr. TH Open. 2020. PMID: 32462111 Free PMC article.

10

Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial.

Mones JV, Streiff MB, Khorana AA, Bendheim GA, Damaraju CV, Wildgoose P, Burton P, Riess H, Soff GA. Mones JV, et al. Among authors: riess h. Res Pract Thromb Haemost. 2021 Jul 20;5(5):e12549. doi: 10.1002/rth2.12549. eCollection 2021 Jul. Res Pract Thromb Haemost. 2021. PMID: 34308096 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

462 results

Search Page

Filters